889 Da vs 4,963 Da: TB-500 vs Thymosin Beta-4 for Researchers
No, they are not reliably the same molecule. What vendors sell as TB-500 is typically a synthetic seven-amino-acid fragment, Ac-LKKTETQ, corresponding to residues 17 through 23 of thymosin beta-4, while the clinical evidence base almost always refers to the full-length, 43-amino-acid protein. Treating the two as interchangeable ignores where the safety and efficacy data actually come from.
TL;DR:
- The TB-500 sold commercially is usually a synthetic peptide fragment, not the full-length thymosin beta-4, leading to significant differences in safety and efficacy data.
- Mass spectrometry can reliably distinguish the 7-amino-acid fragment from the full protein by their molecular weights of approximately 889 Da and 4,963 Da, respectively.
- Most clinical research and safety data pertain to the full-length thymosin beta-4, not to the fragment marketed as TB-500, making extrapolation from one to the other questionable.
- Vendors often sell multiple salts and derivatives under the name TB-500, creating inconsistencies that can undermine scientific reproducibility.
- Verifying the actual molecule in a vial requires requesting MS/MS sequence confirmation, HPLC purity data, and lot-specific certificates, not just relying on label claims.
What vendors and the community call “TB-500”
The term “TB-500” does not point to one defined substance. It functions more like a brand umbrella, and that is precisely the problem researchers run into when they try to compare product listings or reconcile a vendor’s description with the published literature.
In practice, the name has been applied to at least three different things:
- The acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ), which is the substance most commonly found in products actually labeled TB-500.
- Various acetate or salt forms of that same fragment, which carry slightly different molecular weights depending on the counter-ion.
- Occasional, incorrect use of “TB-500” to describe full-length thymosin beta-4 itself, despite the two molecules differing by thousands of daltons.
The FDA’s briefing document on TB-500-related bulk drug substances addressed this directly. The agency found that TB-500 is a common name, not a United States Adopted Name, and that multiple salts and derivatives are being marketed under that single label. Without a USP monograph or a standardized identity, two vials from two different suppliers, both marked “TB-500,” are not guaranteed to contain the same active ingredient at the same purity. For a researcher trying to replicate a protocol or interpret a result, that ambiguity alone can undermine reproducibility before any experiment even starts.
Molecular facts: sequence, acetylation, and weight differences
Sequence and mass are where the distinction stops being a semantic argument and becomes a checkable fact. The fragment sold under the TB-500 name carries the sequence Ac-LKKTETQ, an N-terminal acetylated heptapeptide that maps to residues 17 through 23 of the parent protein. Full-length thymosin beta-4 is a 43-amino-acid peptide that includes the Ac-SDKP motif at its N-terminus, a region entirely absent from the fragment and associated with functions beyond the actin-binding activity the fragment retains.
The practical payoff of knowing these sequences is that mass spectrometry becomes a fast, decisive way to tell the two apart. The molecular weights are far enough apart that confusion requires either an unverified COA or a decision not to check at all.
| Property | TB-500 fragment (Ac-LKKTETQ) | Full-length thymosin beta-4 |
|---|---|---|
| Sequence length | 7 amino acids, residues 17-23 | 43 amino acids |
| N-terminal modification | Acetylated | Acetylated (Ac-SDKP motif) |
| Free base molecular weight | approximately 889 Da per FDA briefing | Approximately 4,963 Da |
| Acetate salt molecular weight | Approximately 949.1 g/mol per FDA briefing | Not typically sold as a distinct salt form |
| Primary detection method | LC-MS/MS, single charge state typical | LC-MS/MS, multiple charge states, deconvolution required |
When a lab runs mass spectrometry on a sample, the fragment typically shows up as a relatively simple, low-charge-state ion given its small size, while the full-length protein produces a more complex spectrum that requires deconvolution across multiple charge states to arrive at the correct monoisotopic mass. A result anywhere near 889 Da confirms the fragment. A result near 4,963 Da confirms the full-length protein. There is no ambiguous middle ground, which is exactly why mass spec, not the label on the vial, should be the final word.
Which molecule the clinical trials actually studied
This is the distinction that matters most for anyone trying to draw conclusions from the published literature. The human clinical record belongs almost entirely to full-length thymosin beta-4, not to the seven-amino-acid fragment.
- A Phase 1 safety study of synthetic full-length thymosin beta-4 administered the peptide intravenously to healthy volunteers across doses of 42 to 1,260 mg and reported that it was tolerated across that range.
- PubMed-indexed clinical studies have evaluated full-length thymosin beta-4 in ophthalmic and wound-related research contexts, with sponsors testing the 43-amino-acid molecule specifically, not a fragment of it.
- The 7-amino-acid fragment marketed as TB-500 has not completed published human clinical trials, which means any benefit attributed to it in research or community discussion is an extrapolation from full-length Tβ4 data or from preclinical fragment work, not a direct finding.
The route and dose mismatch compounds the problem. The Phase 1 safety data for full-length Tβ4 involved intravenous administration at gram-range doses in a controlled clinical setting, while the fragment is typically discussed in subcutaneous, milligram-range protocols in research and biohacking contexts. Carrying a safety conclusion from one route, dose, and molecule over to a structurally different, much smaller peptide administered a different way is not a straightforward substitution, and it is a step we think deserves to be stated plainly rather than assumed.
FDA findings, doping-lab identifications, and quality gaps
The regulatory and analytical record on TB-500 converges on the same concern: inconsistent identity, inconsistent quality documentation. The FDA’s briefing document flagged inconsistent naming, multiple salts and derivatives sold under one label, and a lack of USP monograph, all before even reaching the question of whether a given COA has the data it should.
Independent analytical chemistry adds a second line of evidence. A mass-spectrometry case report tied to anti-doping testing identified the acetylated 17-23 fragment, with a theoretical molecular weight near 888.49, in products marketed as TB-500, using LC-HRMS and de novo sequencing to confirm the match against the expected b and y ion series. That finding lines up with what the FDA described: the name on the label and the molecule in the vial are two separate questions.
For a researcher evaluating a vendor, the quality-control gaps worth checking for include:
- Missing endotoxin testing, which matters for any material intended for injectable research use.
- No aggregate testing, which can hide higher-order impurities that a basic purity percentage will not reveal.
- No confirmed identity test beyond a retention-time match, rather than full MS/MS sequence confirmation.
- Absent lot-level traceability connecting a specific COA to the specific vial in hand.
Pro Tip: Before relying on a vendor’s stated purity percentage, ask whether that number reflects HPLC area-under-curve alone or whether it has been cross-checked against mass spec identity confirmation. The two tell you different things.
How to verify what’s in the vial
Verification does not require a research institution’s budget, but it does require asking for specific documents and reading them critically rather than taking a purity percentage at face value.
- Request sequence confirmation via MS/MS, not just a stated molecular weight, since two different impurities can coincidentally share a similar mass.
- Ask for HPLC purity data alongside the chromatogram itself, so you can check peak shape and the size of the largest impurity, not just a headline number.
- Confirm identity testing was run against a validated reference standard, with retention time alignment reported.
- Request aggregate testing, since aggregation can affect both analytical results and injection safety.
- Confirm endotoxin testing was performed for any material intended for injectable research use.
- Verify lot traceability: the COA should reference a specific lot number that matches the vial, not a generic batch template reused across orders.
- Check storage guidance, since peptides typically require storage at or below -20°C to maintain stability over time.
On the analytical side, expect the deconvoluted mass spectrum to show a clear monoisotopic peak consistent with the expected molecular weight (around 889 Da for the fragment, around 4,963 Da for the full-length protein), with fragmentation patterns matching the anticipated b and y ion series for the stated sequence. A spectrum that does not resolve cleanly to one of those two values is a reason to ask more questions before using the material.
Pro Tip: Keep a retention sample from every lot you work with. If a result later looks inconsistent with your protocol history, you will want material on hand to send for independent testing rather than relying on memory or a vendor’s archived COA.
How we reduce this uncertainty for researchers
We built our testing process around the exact gaps this article describes. Every product is third-party tested for purity, mass accuracy, endotoxins, sterility, and heavy metals, with lot and batch numbers traceable from manufacturer to warehouse so the COA in your hands corresponds to the vial in front of you, not a generic template.
Members can access COAs through QR-linked, lot-specific documentation, which removes the guesswork around whether a given test result actually applies to the batch received. The peptide glossary explains handling and protocol context in plain language, and a built-in dose calculator helps with precise measurement planning once identity and purity have already been confirmed through testing, not assumed from a label.
A verification-first view of peptide research
The naming confusion around TB-500 is not a minor labeling quirk. It is the reason claims about the fragment keep borrowing credibility from full-length thymosin beta-4’s genuinely stronger evidence base, and we think that borrowing deserves more skepticism than it usually gets.
Our stance is straightforward: read any claim that conflates the fragment and the parent protein with caution, and ask what molecule the underlying study actually used. Verification through mass spec and a complete COA should carry more weight than a forum thread or a vendor’s product description. If you want documentation to support your own research records, we are glad to provide it.
— Peppy&Me
Where to find tested TB-500 and BPC-157, and how to work with us
We carry TB-500 and BPC-157 with third-party test summaries and lot-specific COAs available to members, so you can check identity and purity before a protocol begins rather than after a question comes up.
A few practical details worth knowing as you plan an order:
- Orders placed before 2 PM ship the same day within the U.S.
- Full COA access, including mass accuracy and endotoxin results, is available through your member account once logged in.
- Labs and entrepreneurs interested in white-label supply can review our Private Label & Dropshipping Partnership Program, which carries a $500 one-time onboarding fee and a $99 monthly active partnership fee.
- Researchers who need additional lab reports beyond the posted COA can reach our support team directly for documentation requests.
Our full research compounds catalog and accessories are organized the same way, with testing data attached at the lot level rather than the product level.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
Is thymosin beta-4 better than TB-500?
They are not directly comparable because they are different molecules with different evidence bases. Full-length thymosin beta-4 has documented human clinical trial data, while the fragment sold as TB-500 relies mainly on preclinical findings, so “better” depends on which research question you are actually asking.
Is thymosin beta-4 still banned?
Thymosin beta-4 and its derivatives appear on anti-doping prohibited substance lists under category S2, so athletes subject to those rules should treat it as restricted. Researchers working outside competitive sport should still check the regulations that apply to their specific institution or jurisdiction.
What is another name for the TB-500 peptide?
The substance most often found in products labeled TB-500 is more precisely described as Ac-Tβ4(17-23), the acetylated 17-23 fragment of thymosin beta-4, as identified in mass-spectrometry case reports. The FDA briefing document also notes that TB-500 is a common name rather than a standardized designation, which is part of why multiple salts and derivatives share the same label.
How does TB-500 make you feel?
There is no completed human clinical trial data for the seven-amino-acid fragment sold as TB-500, so no verified, research-backed description of subjective effects in humans exists for that specific molecule. Reports describing effects are typically anecdotal or extrapolated from studies of the full-length protein, which was tested under different routes and doses.
Why isn’t TB-500 FDA-approved?
FDA approval requires extensive clinical trials and substantial commercial investment from a sponsor willing to fund that process, and naturally occurring or difficult-to-patent compounds often attract less of that funding despite scientific interest. That is a separate question from safety or legality for research use, and it is addressed directly in the FDA’s briefing document on TB-500-related substances.